Aberrant B-lymphocyte responses in lupus: Inherent or induced and potential therapeutic targets

European Journal of Clinical Investigation

Volumn 43, Issue 8, 2013, Pages 866-880

  Taher, Taher E ^a   Muhammad, Hawzheen A ^a   Rahim, Asad ^a   Flores Borja, Fabian ^b   Renaudineau, Yves ^c   Isenberg, David A ^d   Mageed, Rizgar A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

B lymphocytes; Immunopathology; Lupus; Signalling

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; B LYMPHOCYTE RECEPTOR; CALCIUM ION; CBL PROTEIN; CD45 ANTIGEN; CD79A ANTIGEN; CD79B ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; CYCLIN DEPENDENT KINASE 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RHO KINASE; RITUXIMAB; STRESS ACTIVATED PROTEIN KINASE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNINDEXED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE; CALCIUM SIGNALING; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INFLAMMATION; INNATE IMMUNITY; LUPUS VULGARIS; LYMPHOCYTE PROLIFERATION; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE INJURY;

EID: 84880732657     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12111     Document Type: Review

References (153)

1. Ehrenstein M, Isenberg DA. Systemic lupus erythematosus in adults - clinical features and aetiopathogenesis. Isenberg DA, Maddison P, Woo P, Glass D, Breedveld F, editors. Oxford Textbook of Rheumatology, 3rd Edn. New York: Oxford University Press Inc.; 2004: pp 819-41.
2. Alarcon-Segovia D, Alarcon-Requelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1, 177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005;52:1138-47.
3. Rhodes B, Vyse TJ. The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology 2008;47:1603-11.
4. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus. Gene Ther 2003;10:861-74.
5. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56.
6. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA et al. Mutations in the gene encoding the 30-50 DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007;39:1065-7.
7. Potter PK, Cortes-Hernandez J, Quartier P, Botto M, Walport MJ. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol 2003;170:3223-32.
8. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
9. Li X, Ptacek TS, Brown EE, Edberg JC. Fcgamma receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 2009;10:380-9.
10. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161-72.
11. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10.
12. Kaliyaperumal A, Mohan C, Wu W, Datta SK. Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 1996;183:2459-69.
13. Sieling PA, Porcelli SA, Duong BT, Spada F, Bloom BR, Diamond B et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000;165:5338-44.
14. Herndon TM, Juang YT, Solomou EE, Rothwell SW, Gourley MF, Tsokos GC. Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity. Clin Immunol 2002;103:145-53.
15. Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology 2005;44:989-94.
16. Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25- Foxp3+ T cells in patients with systemic lupus erythematosus. J Immunol 2009;182:1689-95.
17. Bonelli M, Smolen JS, Scheinecker C. T reg and lupus. Ann Rheum Dis 2010;69(Suppl 1):i65-6.
18. Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: activation, anergy and death. Immunol Today 1999;20:119-24.
19. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995;155:2269-81.
20. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology 2007;46:1525-30.
21. Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000;165:6627-34.
22. Linterman MA, Rigby RJ, Wong RK, Yu D, Brink R, Cannons JL et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med 2009;206:561-76.
23. Reininger L, Winkler T, Kalberer CP, Jourdan M, Melchers F, Rolink AG. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB × NZW)F1 mice. J Exp Med 1996;184:853-61.
24. Wakeland EK, Liu K, Graham RR, Behrens TW. Delineating the genetic basis of systemic lupus erythematosus. Immunity 2001;15:397-408.
25. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005;201:703-11.
26. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006;54:408-20.
27. Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002;14:411-9.
28. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006;176:2074-8.
29. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002;297:2063-6.
30. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006;38:550-5.
31. Baudino L, Azeredo da Silveira S, Nakata M, Izui S. Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol 2006;28:175-84.
32. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991;18:1621-2.
33. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8(Suppl 2):S2.
34. Gilbert MR, Wagner NJ, Jones SZ, Wisz AB, Roques JR, Krum KN et al. Autoreactive preplasma cells break tolerance in the absence of regulation by dendritic cells and macrophages. J Immunol 2012;189:711-20.
35. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967-74.
36. Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci USA 2010;107:14292-7.
37. Zouali M, Sarmay G. B lymphocyte signaling pathways in systemic autoimmunity. Arthritis Rheum 2004;50:2730-41.
38. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004;41:599-613.
39. Tolar P, Sohn HW, Pierce SK. The initiation of antigen-induced B cell antigen receptor signaling viewed in living cells by fluorescence resonance energy transfer. Nat Immunol 2005;6:1168-76.
40. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol 2010;28:21-55.
41. Mary C, Laporte C, Parzy D, Santiago ML, Stefani F, Lajaunias F et al. Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice. J Immunol 2000;165:2987-96.
42. Liu K, Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev 2009;8:214-8.
43. Cornall R, Cyster J, Hibbs M, Dunn A, Otipoby K, Clark A et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998;8:497-508.
44. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Hyperresponsive B cells in CD22-deficient mice. Science 1996;274:798-801.
45. Cyster JG, Goodnow CC. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 1995;2:13-24.
46. Jiang Y, Hirose S, Sanokawa-Akakura R, Abe M, Mi X, Li N et al. Genetically determined aberrant down-regulation of FcgammaRIIB1 in germinal center B cells associated with hyper-IgG and IgG autoantibodies in murine systemic lupus erythematosus. Int Immunol 1999;11:1685-91.
47. Liossis SNC, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis M, Sfikakis PP. B-cell kinase Lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 2001;49:157-65.
48. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Decreased Lyn expression and translocation to lipid raft signalling domains in B-lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:3955-65.
49. Taher TE, Parikh K, Flores-Borja F, Mletzko S, Isenberg DA, Peppelenbosch MP et al. Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2010;62:2412-23.
50. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-9.
51. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007;130:25-35.
52. Barber DF, Bartolomé A, Hernandez C, Flores JM, Fernandez-Arias C, Rodríguez-Borlado L et al. Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 2006;176:589-93.
53. Gross AJ, Lyandres JR, Panigrahi AK, Prak ET, DeFranco AL. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol 2009;182:5382-92.
54. Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:291-302.
55. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 2005;23:635-47.
56. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature 2001;409:349-54.
57. Roach T, Slater S, Koval M, White L, Cahir McFarland ED, Okumura M et al. CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion. Curr Biol 1997;7:408-17.
58. Piercy J, Petrova S, Tchilian EZ, Beverley PC. CD45 negatively regulates tumour necrosis factor and interleukin-6 production in dendritic cells. Immunology 2006;118:250-6.
59. Gregori S, Mangia P, Bacchetta R, Tresoldi E, Kolbinger F, Traversari C et al. An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. J Exp Med 2005;201:1293-305.
60. Brooks WP, Lynes MA. Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol 2001;212:24-34.
61. Greer SF, Justement LB. CD45 regulates tyrosine phosphorylation of CD22 and its association with the protein tyrosine phosphatase SHP-1. J Immunol 1999;162:5278-86.
62. Benatar T, Carsetti R, Furlonger C, Kamalia N, Mak TW, Paige CJ. Immunoglobulin-mediated signal transduction in B cells from CD45-deficient mice. J Exp Med 1996;183:329-34.
63. Cyster JG, Healy JI, Kishihara K, Mak TW, Thomas ML, Goodnow CC. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 1996;381:325-8.
64. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999;285:2122-5.
65. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-57.
66. Dhand R, Hara K, Hiles I, Bax B, Gout I, Panayotou G et al. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 1994;13:511-21.
67. Lehmann K, Müller JP, Schlott B, Skroblin P, Barz D, Norgauer J et al. PI3Kgamma controls oxidative bursts in neutrophils via interactions with PKCalpha and p47phox. Biochem J 2009;419:603-10.
68. Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 2007;104:7809-14.
69. Pirola L, Zvelebil MJ, Bulgarelli-Leva G, Van Obberghen E, Waterfield MD, Wymann MP. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem 2001;276:21544-54.
70. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 2002;13:169-72.
71. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000;287:1049-53.
72. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-6.
73. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196:753-63.
74. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22:8580-91.
75. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006;107:642-50.
76. Suárez-Fueyo A, Barber DF, Martínez-Ara J, Zea-Mendoza AC, Carrera AC. Enhanced phosphoinositide 3-kinase δ activity is a frequent event in systemic lupus erythematosus that confers resistance to activation-induced T cell death. J Immunol 2011;187:2376-85.
77. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 2005;11:933-5.
78. Maxwell MJ, Tsantikos E, Kong AM, Vanhaesebroeck B, Tarlinton DM, Hibbs ML. Attenuation of phosphoinositide 3-kinase δ signaling restrains autoimmune disease. J Autoimmun 2012;38:381-91.
79. Omori SA, Rickert RC. Phosphatidylinositol 3-kinase (PI3K) signalling and regulation of the antibody response. Cell Cycle 2007;6:397-402.
80. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signalling. Immunity 2006;25:545-57.
81. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-4.
82. Durand CA, Hartvigsen K, Fogelstrand L, Kim S, Iritani S, Vanhaesebroeck B et al. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol 2009;183:5673-84.
83. Beer-Hammer S, Zebedin E, von Holleben M, Alferink J, Reis B, Dresing P et al. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J Leukoc Biol 2010;87:1083-95.
84. Dil N, Marshall AJ. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation. Mol Immunol 2009;46:1970-8.
85. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
86. Rommel C, Camps M, Ji H. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007;7:191-201.
87. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-43.
88. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35.
89. Verdolini R, Bugatti L, Giangiacomi M, Nicolini M, Filosa G, Cerio R. Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 2002;146:877-81.
90. Tomita H, Yamada M, Sekigawa I, Yoshiike T, Iida N, Hashimoto H. Systemic lupus erythematosus-like autoimmune abnormalities induced by bacterial infection. Clin Exp Rheumatol 2003;21:497-9.
91. Ehlers M, Fukuyama H, McGaha TL, Aderem A, Ravetch JV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006;203:553-61.
92. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 2008;29:249-60.
93. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann N Y Acad Sci 2008;1143:21-34.
94. Sadanaga A, Nakashima H, Akahoshi M, Masutani K, Miyake K, Igawa T et al. Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 2007;56:1618-28.
95. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007;18:1721-31.
96. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006;25:417-28.
97. Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601-11.
98. Eloranta ML, Lövgren T, Finke D, Mathsson L, Rönnelid J, Kastner B et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009;60:2418-27.
99. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008;28:799-809.
100. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000;1:11-21.
101. Dugas B, Calenda A, Delfraissy JF, Vazquez A, Bach JF, Galanaud P. The cytosolic free calcium in anti-mu-stimulated human B cells is derived partly from extracellular medium and partly from intracellular stores. Eur J Immunol 1987;17:1323-8.
102. Peinelt C, Vig M, Koomoa DL, Beck A, Nadler MJ, Koblan-Huberson M et al. Amplification of CRAC current by STIM1 and CRACM1 (Orai1). Nat Cell Biol 2006;8:771-3.
103. Wu MM, Buchanan J, Luik RM, Lewis RS. Ca2+ store depletion causes STIM1 to accumulate in ER regions closely associated with the plasma membrane. J Cell Biol 2006;174:803-13.
104. Putney JW Jr, Broad LM, Braun FJ, Lievremont JP, Bird GS. Mechanisms of capacitative calcium entry. J Cell Sci 2001;114:2223-9.
105. Lyubchenko T, dal Porto J, Cambier JC, Holers VM. Coligation of the B cell receptor with complement receptor type 2 (CR2/CD21) using its natural ligand C3dg: activation without engagement of an inhibitory signaling pathway. J Immunol 2005;174:3264-72.
106. Kulik L, Marchbank KJ, Lyubchenko T, Kuhn KA, Liubchenko GA, Haluszczak C et al. Intrinsic B cell hypo-responsiveness in mice prematurely expressing human CR2/CD21 during B cell development. Eur J Immunol 2007;37:623-33.
107. Lyubchenko T, Dal Porto JM, Holers VM, Cambier JC. Cutting edge: complement (C3d)-linked antigens break B cell anergy. J Immunol 2007;179:2695-9.
108. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol 2007;7:633-43.
109. Yarkoni Y, Getahun A, Cambier JC. Molecular underpinning of B-cell anergy. Immunol Rev 2010;237:249-63.
110. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat Immunol 2005;6:1160-7.
111. Bednarski JJ, Lyssiotis CA, Roush R, Boitano AE, Glick GD, Opipari AW Jr. A novel benzodiazepine increases the sensitivity of B cells to receptor stimulation with synergistic effects on calcium signaling and apoptosis. J Biol Chem 2004;279:29615-21.
112. Crocas SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2012;50:1424-30.
113. Youinou P, Taher TE, Mankaï A, Berthou C, Mageed RA. Anti-CD20 in targeting B-lymphocytes for the treatment of autoimmune diseases. Clinical benefits and insights into the role of B-lymphocytes in disease pathology. Immunol Endocr Metab Agents Med Chem 2008;8:222-34.
114. Lu T, Ng KP, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
115. Favas C, Isenberg DA. B cell depletion in SLE - what are the current prospects for its acceptance. Nat Rev Rheumatol 2009;5:711-6.
116. Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013;15(Suppl 1):S2.
117. Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol 2013;146:90-103.
118. Ezeonyeji AN, Isenberg DA. Early treatment of rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid sparing regime. Rheumatology 2012;51:476-81.
119. Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R204.
120. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of Epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74.
121. Harvey PR, Gordon C. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. BioDrugs 2013;27:85-95.
122. Alarcón-Segovia D, Tumlin J, Furie RA, McKay JD, Cardiel MH, Strand V et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
123. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80.
124. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-4.
125. Ramanujam M, Wang X, Huang W, Schiffer L, Grimaldi C, Akkerman A et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004;173:3524-34.
126. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50.
127. Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109.
128. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
129. Dooley M, Houssiau F, Aranow C, D'Cruz D, Askanase A, Roth D et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63-72.
130. Mok MY. The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 2010;13:3-11.
131. La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy 2010;2:575-82.
132. Stohl W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 2012;14:303-9.
133. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, for the IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154. Arthritis Rheum 2002;46:3251-8.
134. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7.
135. Ye X, Zhu T, Bastacky S, McHale T, Li J, Xiao X. Prevention and reversal of lupus in NZB/NZW mice by costimulatory blockade with adeno-associated virus-mediated gene transfer. Arthritis Rheum 2005;52:3975-86.
136. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
137. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 2012;64:3660-5.
138. Ding H, Wu X, Wu J, Yagita H, He Y, Zhang J et al. Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. Clin Immunol 2006;118:258-67.
139. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91.
140. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81.
141. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013;72:118-28.
142. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542-52.
143. Llorente L, Richaud-Patin Y, García-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
144. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of TNFα blockage in systemic lupus erythematosus- an open label study. Arthritis Rheum 2004;50:3161-9.
145. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
146. Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z et al. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc Natl Acad Sci USA 2009;106:5294-9.
147. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666-76.
148. Merrill JT, Wallace DJ, Petri M, Kirou KA, Yao Y, White WI et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011;70:1905-13.
149. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987;166:798-803.
150. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 2000;106:207-15.
151. ClinicalTrials.gov. "Safety Study of AMG 811 in Subjects with Systemic Lupus Erythematosus With and Without Glomerulonephritis, " (NCT00818948), August 2011. Available at: http://www.clinicaltrials.gov.
152. Postal M, Costallat LT, Appenzeller S. Biological therapy in systemic lupus erythematosus. Int J Rheumatol 2012;2012:578641.
153. Verweij CL, Vosslamber S. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med 2011;11:229-36.